The Effects of Inorganic Nitrate on Cardiac Muscle in Angina
CompletedPhase 2NCT02078921
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Previous studies have shown that interventions which modestly increase blood nitrite\_ improve skeletal muscle function on exercise while sparing oxygen, and have been also shown to open up the blood flow during periods of oxygen deprivation. Inorganic nitrate in the diet is absorbed into the bloodstream, concentrated and reduced by bacteria in the mouth to nitrite, which is then absorbed into the bloodstream. . The purpose of this study is to look at the effects of oral inorganic nitrate supplementation on clinical markers of heart ischaemia and the frequency of angina.
Study details
- Official title
- The Effects of Inorganic Nitrate on Cardiac Muscle: Physiology, Pharmacology and Therapeutic Potential in Patients Suffering From Angina
- Conditions
- Interventions
- Drug: Sodium Nitrate
- Drug: Placebo
- Sponsor
- University of Aberdeen
- Start date
- 2012-10
- Primary completion
- 2014-12
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients aged 18 and over with chronic stable angina (≥2 months duration). Inclusion Criteria Following screening visit: * A positive exercise ECG (1mmSTD at J+0.08 seconds) on a modified Bruce protocol treadmill exercise test. * A positive dobutamine stress echocardiogram, * and/or a positive myocardial perfusion scan (MPI), * and/or a positive coronary angiogram. Exclusion Criteria: * Unable to do exercise test * Women of child bearing potential * If of a racial origin at risk of glucose-6-phosphate dehydrogenase (G6PD) deficiency, G6PD will be excluded prior to inclusion in the study * Resting STD\>=1mm * NYHA 3 or 4 HF or LVEF\<45% * Myocardial infarction or revascularisation within the last two months * Left bundle branch block (LBBB)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02078921